452 related articles for article (PubMed ID: 27666543)
1. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.
Niknafs YS; Han S; Ma T; Speers C; Zhang C; Wilder-Romans K; Iyer MK; Pitchiaya S; Malik R; Hosono Y; Prensner JR; Poliakov A; Singhal U; Xiao L; Kregel S; Siebenaler RF; Zhao SG; Uhl M; Gawronski A; Hayes DF; Pierce LJ; Cao X; Collins C; Backofen R; Sahinalp CS; Rae JM; Chinnaiyan AM; Feng FY
Nat Commun; 2016 Sep; 7():12791. PubMed ID: 27666543
[TBL] [Abstract][Full Text] [Related]
2. LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer.
Ma Y; Bu D; Long J; Chai W; Dong J
J Cell Physiol; 2019 Mar; 234(3):2880-2894. PubMed ID: 30203615
[TBL] [Abstract][Full Text] [Related]
3. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
4. The clinical significance of circulating DSCAM-AS1 in patients with ER-positive breast cancer and construction of its competitive endogenous RNA network.
Moradi MT; Fallahi H; Rahimi Z
Mol Biol Rep; 2020 Oct; 47(10):7685-7697. PubMed ID: 33040318
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
[TBL] [Abstract][Full Text] [Related]
6. Selective expression of long non-coding RNAs in a breast cancer cell progression model.
Tracy KM; Tye CE; Page NA; Fritz AJ; Stein JL; Lian JB; Stein GS
J Cell Physiol; 2018 Feb; 233(2):1291-1299. PubMed ID: 28488769
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of the long noncoding RNAs DSCAM-AS1 and MANCR is a potential diagnostic marker for breast carcinoma.
Tahmouresi F; Razmara E; Pakravan K; Mossahebi-Mohammadi M; Rouhollah F; Montazeri M; Sarrafzadeh A; Fahimi H; Babashah S
Biotechnol Appl Biochem; 2021 Dec; 68(6):1250-1256. PubMed ID: 33012018
[TBL] [Abstract][Full Text] [Related]
8. DSCAM-AS1 up-regulation in invasive ductal carcinoma of breast and assessment of its potential as a diagnostic biomarker.
Khorshidi H; Azari I; Oskooei VK; Taheri M; Ghafouri-Fard S
Breast Dis; 2019; 38(1):25-30. PubMed ID: 30594914
[TBL] [Abstract][Full Text] [Related]
9. DSCAM-AS1 regulates the G
Sun W; Li AQ; Zhou P; Jiang YZ; Jin X; Liu YR; Guo YJ; Yang WT; Shao ZM; Xu XE
Cancer Med; 2018 Dec; 7(12):6137-6146. PubMed ID: 30430768
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA (lncRNA) DSCAM-AS1 is upregulated in breast cancer.
Tarighi M; Khalaj-Kondori M; Hosseinzadeh A; Abtin M
Breast Dis; 2021; 40(2):63-68. PubMed ID: 33554879
[TBL] [Abstract][Full Text] [Related]
11. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer.
Ma T; Liang Y; Li Y; Song X; Zhang N; Li X; Chen B; Zhao W; Wang L; Yang Q
Cell Signal; 2020 Apr; 68():109536. PubMed ID: 31927036
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic long noncoding RNA landscape in breast cancer.
Xu S; Kong D; Chen Q; Ping Y; Pang D
Mol Cancer; 2017 Jul; 16(1):129. PubMed ID: 28738804
[TBL] [Abstract][Full Text] [Related]
13. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
14. Identification of Long Noncoding RNAs as Predictors of Survival in Triple-Negative Breast Cancer Based on Network Analysis.
Li XX; Wang LJ; Hou J; Liu HY; Wang R; Wang C; Xie WH
Biomed Res Int; 2020; 2020():8970340. PubMed ID: 32190687
[TBL] [Abstract][Full Text] [Related]
15. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer.
Peng WX; Huang JG; Yang L; Gong AH; Mo YY
Mol Cancer; 2017 Oct; 16(1):161. PubMed ID: 29041978
[TBL] [Abstract][Full Text] [Related]
16. LncRNA DSCAM-AS1: A Pivotal Therapeutic Target in Cancer.
Hu C
Mini Rev Med Chem; 2023; 23(5):530-536. PubMed ID: 35996247
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
Li X; Wu Y; Liu A; Tang X
Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
[TBL] [Abstract][Full Text] [Related]
18. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer.
Shi Q; Li Y; Li S; Jin L; Lai H; Wu Y; Cai Z; Zhu M; Li Q; Li Y; Wang J; Liu Y; Wu Z; Song E; Liu Q
Nat Commun; 2020 Nov; 11(1):5513. PubMed ID: 33139730
[TBL] [Abstract][Full Text] [Related]
19.
Fang Z; Wang Y; Wang Z; Xu M; Ren S; Yang D; Hong M; Xie W
Cancer Res; 2020 Oct; 80(20):4399-4413. PubMed ID: 32826278
[TBL] [Abstract][Full Text] [Related]
20. Luminal lncRNAs Regulation by ERα-Controlled Enhancers in a Ligand-Independent Manner in Breast Cancer Cells.
Miano V; Ferrero G; Rosti V; Manitta E; Elhasnaoui J; Basile G; De Bortoli M
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]